Navigation Links
Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio
Date:12/30/2010

ST. LOUIS, Dec. 30, 2010 /PRNewswire-FirstCall/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) announced today it has acquired all outstanding shares of Cerilliant Corporation of Round Rock, Texas to strengthen the Company's analytical chemistry product portfolio and to continue to deliver on its strategic growth plans. Cerilliant, a leading supplier of high quality reference standards and materials, provides products that support the clinical diagnostics, environmental, nutraceutical, pharmaceutical, forensic and clinical toxicology markets. Terms of the purchase were not disclosed. The Company expects this acquisition to be neutral to mildly accretive to earnings per share in 2011. Cerilliant has been a portfolio company of Argenta Partners of Dallas, Texas for the past 10 years.  

Cerilliant brings to Sigma-Aldrich over 2,800 products and more than 30 years of expertise in the design, development, synthesis, characterization and packaging of analytical standards, calibrators, controls and certified reference materials that are used in a wide range of analytical applications. The standards company is well known for its visionary approach to serving these growing industries with a continually expanding line of innovative new products and sustains a modern, robust quality system which incorporates cGMP, GLP and ISO requirements. Cerilliant is accredited to ISO Guide 34, ISO/IEC 17025 and is certified to ISO 9001:2008. Its extensive capabilities complement Sigma-Aldrich's existing Fluka® and Supelco® analytical brands and will expand the Company's analytical customer base and markets. Cerilliant employs 65 people at its state-of-the-art laboratory and manufacturing facility in Round Rock, Texas. Its website can be accessed at www.cerilliant.com.

"Cerilliant's strong product suite and solid relationships with cus
'/>"/>

SOURCE Sigma-Aldrich Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
3. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
4. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
5. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
6. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
7. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
8. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
9. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
10. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
11. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... Sterlitech is proud to debut its multi-line, ... 2015 AMTA Membrane Technology Conference in Orlando. This ... of engineering and customer feedback, which has resulted in ... applications across an array of disciplines. It is ... needs of researchers and engineers alike and is ideal ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... today published analyses of its second-generation map of ... markers than the initial version unveiled in 2005. ... consortium describes how the higher resolution map offers ... common diseases, explore the structure of human genetic ...
... FRANCISCO, Calif., Oct. 17 Monogram,Biosciences, Inc., (Nasdaq: ... on Wednesday, October 24, 2007 at 4:30 p.m. (Eastern ... will be hosted by Mr.,William D. Young, Chairman and ... teleconference, please call (877) 548-7912,or (719) 325-4878 for international ...
... ARNA ) today reported financial results for the ... the third quarter of 2007 were $5.0 million, compared,to ... revenues in the first,nine months of 2007 were $14.8 ... of 2006. Revenues in the first nine months of ...
Cached Biology Technology:Consortium publishes Phase II map of human genetic variation 2Consortium publishes Phase II map of human genetic variation 3Consortium publishes Phase II map of human genetic variation 4Consortium publishes Phase II map of human genetic variation 5Consortium publishes Phase II map of human genetic variation 6Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to ... biometrics technology is to ensure that an individual is who ... technology may make use of a person,s unique physical characteristics, ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Robert Burns compared his love to a red, red rose, ... rather than being topped by a lovely, fragrant bloom, a ... crowned by a homely second root. , Researchers at the ... plant Arabidopsis thaliana rather than the elegant rose recently determined ...
... University at Buffalo have received a $2.5 million five-year ... dysfunction called "hibernating myocardium" that can cause disabling heart ... a condition in which myocytes (cells in the heart's ... that receive reduced blood flow over an extended period ...
... University of Florida scientists conducting experiments with mice have ... of cells in the eye essential for healthy vision. ... cell layer vital for eyesight called the retinal pigment ... writing in a recent issue of Investigative Ophthalmology & ...
Cached Biology News:Salk scientists get to the root of plant cell fate 2Salk scientists get to the root of plant cell fate 3Reversing 'hibernating' heart muscle focus of UB researchers 2Bone marrow may restore cells lost in vision diseases 2Bone marrow may restore cells lost in vision diseases 3
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: